Evolus price target raised to $27 from $16 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Evolus to $27 from $16 and keeps a Buy rating on the shares post the Q2 results. Jeuveau keeps gaining traction, while Evolysse adds value to the company’s long-term growth strategy, the analyst tells investors in a research note.